Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq
Other stock markets
 03:59:46 2024-06-04 pm EDT 		5-day change 1st Jan Change
1.445 USD -2.36% Intraday chart for Marinus Pharmaceuticals, Inc. -3.67% -86.71%
May. 17 Sector Update: Health Care Stocks Mixed Late Afternoon MT
May. 17 Sector Update: Health Care MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation
Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study
Marinus Pharmaceuticals inicia un programa de acceso global para ZTALMY® (ganaxolona) en suspensión oral CV
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.
  5. Other languages